Blog
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as Fn14), a member of the tumor necrosis factor receptor (TNFR) family. Overexpressed in many solid tumo
…
17th Dec 2025
Targeting IL-10R: Enhancing Immune Activation in Cancer
Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
…
12th Dec 2024
Tiragolumab Biosimilar: Enhancing Immune Checkpoint Therapy with TIGIT Inhibition
Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activity in
…
12th Dec 2024
Vibostolimab Biosimilar: Advancing Immune Activation with TIGIT Inhibition
Vibostolimab is a monoclonal antibody that targets TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activit
…
12th Dec 2024
Pinatuzumab Biosimilar: Advancing CD22-Targeted Therapy in B-Cell Malignancies
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD22, a cell surface marker highly expressed on malignant B cells. It delivers a potent cytotoxic agent directly to CD22-
…
12th Dec 2024
Tesnatilimab Biosimilar: Advancing CD38-Targeted Therapy
Tesnatilimab is a monoclonal antibody targeting CD38, a transmembrane glycoprotein highly expressed on malignant plasma cells in multiple myeloma (MM) and other hematologic malignancies.
…
10th Dec 2024
Sacituzumab Biosimilar: Advancing Trop-2-Targeted Cancer Therapy
Sacituzumab govitecan is an innovative antibody-drug conjugate (ADC) targeting Trop-2, a transmembrane glycoprotein overexpressed in many epithelial cancers. By selectively delivering a c
…
10th Dec 2024
Ipilimumab Biosimilar: Expanding Access to CTLA-4 Inhibition
Ipilimumab (Yervoy) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a key immune checkpoint receptor. By inhibiting CTLA-4, Ipilimumab enhances T-
…
9th Dec 2024
Amatuximab Biosimilar: Advancing Mesothelin-Targeted Therapy for Cancer
Amatuximab is a monoclonal antibody targeting mesothelin, a tumor-associated antigen overexpressed in several aggressive cancers, including mesothelioma and pancreatic cancer. By binding
…
8th Dec 2024
Iscalimab Biosimilar: Advancing CD40-Targeted Therapy for Immune Modulation
Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key receptor in the immune system. By blocking CD40-CD40L interactions, Iscalimab inhibits immune activation, making it a pro
…
7th Dec 2024
Varlilumab Biosimilar: Enhancing Immune Activation via CD27-Targeted Therapy
Varlilumab is a monoclonal antibody targeting CD27, a critical costimulatory receptor in the immune system. Acting as a CD27 agonist, Varlilumab enhances T-cell activation and effector fu
…
5th Dec 2024
Brentuximab Biosimilar: Advancing CD30-Targeted Therapy
Brentuximab vedotin is a CD30-targeting antibody-drug conjugate (ADC) approved for treating CD30-positive malignancies, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (A
…
5th Dec 2024
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024
Indatuximab Biosimilar: A New Frontier in CD138-Targeted Cancer Therapy
Indatuximab ravtansine is a CD138-targeting antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other CD138-expressing cancers. By delivering a cytotoxic payl
…
4th Dec 2024
Vopratelimab Biosimilar: A Next-Generation ICOS Agonist for Cancer Immunotherapy
Vopratelimab is a monoclonal antibody targeting inducible T-cell costimulator (ICOS), a key receptor involved in T-cell activation and immune regulation. By selectively activating ICOS, V
…
4th Dec 2024
CB6 Biosimilar: Targeting SARS-CoV-2 with Cost-Effective Monoclonal Antibody Therapy
CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind
…
4th Dec 2024
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting
What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
…
27th Nov 2024
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research
Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.
…
27th Nov 2024
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond
What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
…
27th Nov 2024
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications
Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
…
26th Nov 2024
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars
Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
…
26th Nov 2024
Daratumumab: Advancing Research in Multiple Myeloma and Beyond
Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
…
26th Nov 2024
MHC Class I vs MHC Class II: Key Differences and Functions
Major Histocompatibility Complex (MHC) molecules are essential for immune recognition and response. They are specialized glycoproteins that present antigens to T cells, allowing the immun
…
22nd Nov 2024
Immunoglobulins: Structure, Function, and Clinical Importance
Immunoglobulins (Igs), also known as antibodies, are glycoproteins produced by B cells and plasma cells. They play a central role in the immune system by identifying and neutralizing path
…
20th Nov 2024